enVVeno Medical (enVVeno Medical) Float Percentage Of Total Shares Outstanding : 99.61% (As of Jun. 08, 2024)

View and export this data going back to 2018. Start your Free Trial

What is enVVeno Medical Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, enVVeno Medical's float shares is 13.28 Mil. enVVeno Medical's total shares outstanding is 13.33 Mil. enVVeno Medical's float percentage of total shares outstanding is 99.61%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, enVVeno Medical's Insider Ownership is 8.86%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, enVVeno Medical's Institutional Ownership is 8.41%.

enVVeno Medical Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

enVVeno Medical's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	13.28	/	13.33
	=	99.61%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

enVVeno Medical (enVVeno Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » enVVeno Medical Corp (NAS:NVNO) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

5HJ:Germany 5HJ:Germany

Address

70 Doppler, Irvine, CA, USA, 92618

Website

https://www.envveno.com

enVVeno Medical Corp is a medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its lead product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).

Executives

Hamed Alavi	officer: Chief Technology Officer	ENVVENO MEDICAL CORPORATION, 70 DOPPLER, IRVINE CA 92618
Francis Duhay	director	HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Sanjay Shrivastava	director	HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Robert Andrew Berman	director, officer: CEO	C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Matthew Jenusaitis	director	2 GOODYEAR, IRVINE CA 92618
Robert Gray	director	70 DOPPLER, IRVINE CA 92618
Marc H. Glickman	officer: See Remarks	70 DOPPLER, IRVINE CA 92618
Biodyne Holding, S.a.	10 percent owner	13 RUE DE LA GARE, MORGES V8 1110
Craig Glynn	officer: Chief Financial Officer	70 DOPPLER, IRVINE CA 92618
Marcus W. Robins	director	C/O HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Robert A Rankin	officer: Chief Financial Officer	9200 SUNSET BLVD., SUITE 425, WEST HOLLYWOOD CA 90069
Browston Trading Ltd	10 percent owner	P.O. BOX 20533, NICOSIA G4 1660
Robert W. Doyle	director	70 DOPPLER, IRVINE CA 92618
Robert A. Anderson	director	70 DOPPLER, IRVINE CA 92618
Susan Montoya	officer: See Remarks	70 DOPPLER, IRVINE CA 92618